Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CERTIFY: Certoparin vs UFH for VTE Prophylaxis in Acutely Ill Medical Patients
NCT00451412Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2007
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of certoparin in venous thromboembolism (VTE) (2 arms), sponsored by Novartis. Primary endpoint: Incidence of venous thromboembolism at 20 days. Started Jan 2007; status: completed.
02
Drugs
certoparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00451412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00451412.